3M Company

(New York Stock Exchange)
Back to all articles
Bullish +75

3M earnings suggest it's becoming a 'great growth stock' again: find out more

Earnings report Guidance raised AI-generated analysis

πŸ“ˆ 3M reported Q3 revenue of $6.5 billion, a 4.1% increase that beat analyst expectations of $6.25 billion.

πŸ’° Adjusted earnings per share reached $2.19, surpassing the consensus estimate of $1.98 per share.

πŸš€ Management raised full-year guidance to $8.0 adjusted EPS with at least 2.0% organic growth.

πŸ“Š Adjusted gross margins expanded by 280 basis points, indicating strong operational efficiency gains.

πŸ”§ The company successfully spun off its healthcare division into Solventum to streamline operations.

πŸ“‰ Legacy risks including groundwater contamination and litigation are now largely resolved according to management.

πŸ“ˆ Stock price rallied over 25% from year-to-date lows following the earnings beat and guidance raise.

πŸ’Ό Wall Street consensus rating is 'moderate buy' with a high price target of $185 indicating 15% upside.

πŸ’΅ The company offers a dividend yield of 1.82%, attracting income-focused investors.

🎯 Jim Cramer and analysts view the spin-off as a strategic unlock for long-term shareholder value.

Bullish Signals
  • 3M reported Q3 revenue of $6.5 billion, beating analyst estimates of $6.25 billion by $250 million.
  • Adjusted earnings per share of $2.19 exceeded the consensus forecast of $1.98, demonstrating strong profitability.
  • Management raised full-year adjusted EPS guidance to $8.0 with a minimum 2.0% organic growth target.
  • Adjusted gross margins expanded by 280 basis points, reflecting significant operational improvements and cost control.
  • The spin-off of the healthcare division into Solventum is expected to sharpen focus on core industrial segments.
  • Legacy liabilities regarding groundwater contamination and litigation are largely resolved, reducing balance sheet risk.
  • Stock price has rallied over 25% from year-to-date lows following the positive earnings surprise and guidance raise.
  • Analyst consensus remains 'moderate buy' with a high price target of $185 suggesting substantial upside potential.
Full Analysis
3M reported third-quarter financial results that significantly exceeded analyst expectations, with revenue rising 4.1% to $6.5 billion and adjusted earnings per share reaching $2.19 against a consensus of $1.98. This strong performance drove the stock price up more than 3% in early trading, marking a broader rally of over 25% from its year-to-date low as investors react positively to the company's operational improvements. Following the earnings release, management raised its full-year guidance, projecting adjusted EPS of $8.0 with at least 2.0% organic growth. The company highlighted a substantial expansion in adjusted gross margins of 280 basis points, signaling a robust turnaround in operations. Additionally, the spin-off of its healthcare division into Solventum is viewed as a strategic move to streamline focus on core industrial and consumer segments. Analysts and market observers, including Jim Cramer, are increasingly viewing 3M as a growth stock again, citing resolved legacy issues like groundwater contamination and litigation risks. Wall Street maintains a 'moderate buy' consensus with price targets reaching $185, suggesting potential upside of approximately 15%. The company also retains an attractive dividend yield of 1.82%, supporting its appeal to income-focused investors.